Literature DB >> 20472355

On the importance of accounting for competing risks in pediatric brain cancer: II. Regression modeling and sample size.

Bee-Choo Tai1, Richard Grundy, David Machin.   

Abstract

PURPOSE: To accurately model the cumulative need for radiotherapy in trials designed to delay or avoid irradiation among children with malignant brain tumor, it is crucial to account for competing events and evaluate how each contributes to the timing of irradiation. An appropriate choice of statistical model is also important for adequate determination of sample size. METHODS AND MATERIALS: We describe the statistical modeling of competing events (A, radiotherapy after progression; B, no radiotherapy after progression; and C, elective radiotherapy) using proportional cause-specific and subdistribution hazard functions. The procedures of sample size estimation based on each method are outlined. These are illustrated by use of data comparing children with ependymoma and other malignant brain tumors. The results from these two approaches are compared.
RESULTS: The cause-specific hazard analysis showed a reduction in hazards among infants with ependymoma for all event types, including Event A (adjusted cause-specific hazard ratio, 0.76; 95% confidence interval, 0.45-1.28). Conversely, the subdistribution hazard analysis suggested an increase in hazard for Event A (adjusted subdistribution hazard ratio, 1.35; 95% confidence interval, 0.80-2.30), but the reduction in hazards for Events B and C remained. Analysis based on subdistribution hazard requires a larger sample size than the cause-specific hazard approach.
CONCLUSIONS: Notable differences in effect estimates and anticipated sample size were observed between methods when the main event showed a beneficial effect whereas the competing events showed an adverse effect on the cumulative incidence. The subdistribution hazard is the most appropriate for modeling treatment when its effects on both the main and competing events are of interest.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20472355     DOI: 10.1016/j.ijrobp.2009.12.024

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

1.  The use and interpretation of competing risks regression models.

Authors:  James J Dignam; Qiang Zhang; Masha Kocherginsky
Journal:  Clin Cancer Res       Date:  2012-01-26       Impact factor: 12.531

2.  Smoking cessation and mortality among middle-aged and elderly Chinese in Singapore: the Singapore Chinese Health Study.

Authors:  Sin How Lim; Bee Choo Tai; Jian-Min Yuan; Mimi C Yu; Woon-Puay Koh
Journal:  Tob Control       Date:  2011-12-14       Impact factor: 6.953

3.  Analysis and design of randomised clinical trials involving competing risks endpoints.

Authors:  Bee-Choo Tai; Joseph Wee; David Machin
Journal:  Trials       Date:  2011-05-19       Impact factor: 2.279

4.  A tutorial on sensitivity analyses in clinical trials: the what, why, when and how.

Authors:  Lehana Thabane; Lawrence Mbuagbaw; Shiyuan Zhang; Zainab Samaan; Maura Marcucci; Chenglin Ye; Marroon Thabane; Lora Giangregorio; Brittany Dennis; Daisy Kosa; Victoria Borg Debono; Rejane Dillenburg; Vincent Fruci; Monica Bawor; Juneyoung Lee; George Wells; Charles H Goldsmith
Journal:  BMC Med Res Methodol       Date:  2013-07-16       Impact factor: 4.615

5.  Risk factors for hospital and long-term mortality of critically ill elderly patients admitted to an intensive care unit.

Authors:  A Mukhopadhyay; B C Tai; K C See; W Y Ng; T K Lim; S Onsiong; S Ee; M J Chua; P R Lee; M L Loh; J Phua
Journal:  Biomed Res Int       Date:  2014-12-16       Impact factor: 3.411

6.  Evaluation of Death among the Patients Undergoing Permanent Pacemaker Implantation: A Competing Risks Analysis.

Authors:  Haleh Ghaem; Mohammad Ghorbani; Samira Zare Dorniani
Journal:  Iran J Public Health       Date:  2017-06       Impact factor: 1.429

7.  Chemotherapy and adverse cardiovascular events in colorectal cancer patients undergoing surgical resection.

Authors:  Chieh Yang Koo; Bee-Choo Tai; Dedrick Kok Hong Chan; Li Ling Tan; Ker Kan Tan; Chi-Hang Lee
Journal:  World J Surg Oncol       Date:  2021-01-21       Impact factor: 2.754

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.